Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Clin Cancer Res. 2018 Jun 5;24(19):4865–4873. doi: 10.1158/1078-0432.CCR-18-0202

Figure 1. Chemotherapy impact upon OS in DSRCT patients.

Figure 1

(A) Overall survival for all patients according to treatment era (before 2003, after 2003, and both). (B) Overall survival in patients who achieved clinical benefit or had progressive disease to their initial chemotherapy regimen. (C) Stratification of overall survival by RECIST response to the first chemotherapy regimen each patient received, and (D) Survival effect resulting from standard 3-week chemotherapy treatment vs. dose-dense treatment, when the traditional neoadjuvant VAC/IE regimen was provided. PD = partial disease; SD = stable disease; PR = partial response; CR = complete response.